Background: Drug-drug interactions (DDIs) are of major concern in oncology, since cancer patients typically take many concomitant medications. Retrospective studies have been conducted to determine the prevalence of DDIs. However, prospective studies on DDIs needing interventions in cancer patients have not yet been carried out. Therefore, a prospective study was designed to identify DDIs leading to interventions among ambulatory cancer patients receiving anticancer treatment.
. Two of these studies were conducted in ambulatory cancer patients receiving i.v. anticancer treatment and, in these studies, it was concluded that 27%-58% of all patients had at least one DDI [4, 6] . Comparable results were found in a multicenter study on ambulatory cancer patients treated with oral anticancer medication [3] . Several studies also identified determinants for DDIs in anticancer therapy: the number of comedications, the use of over-the-counter (OTC) drugs, the type of (anticancer) medication and the presence of certain tumors were associated with the occurrence of DDIs [3, 4, 6] . However, due to the retrospective setting of these studies, it is unknown whether these DDIs were true medication errors, or if these DDIs represented drug-drug combinations selected intentionally by the (hemato)oncologist (and handled e.g. by intensive monitoring). Therefore, a prospective study was designed to identify DDIs leading to clinical interventions among ambulatory cancer patients starting a new oral and/or i.v. anticancer regimen. The secondary objective of this study was to obtain more information on potential determinants for DDIs leading to interventions.
patients and methods study design and patients
A prospective intervention study was designed for patients treated with anticancer drugs at the Erasmus MC Cancer Institute (Rotterdam, The Netherlands). All patients treated in the outpatient department with oral or i.v. anticancer drugs, starting a new regimen between April 2013 and February 2014, were asked to participate. Exclusion criteria were: age <18 years, language barrier and the use of anticancer drugs for nonmalignant disease. This study was approved by the medical ethics committee of the Erasmus Medical Center.
procedures
Patients were asked to participate in this study before the start of a new treatment regimen of anticancer therapy. Data on demographic characteristics, use of co-medication, OTC drugs, relevant consumption of food (supplements), such as grapefruit juice, and comorbidities were collected in a structured interview with the patient. To help identify the actual use of the co-medication, a 6-month overview of prescribed medication was collected from the community pharmacy. Data on the use of anticancer drugs, supportive care drugs, diagnosis and treatment intent ( palliative/curative) were collected by medical chart review. Patients were also asked if the medical oncologist had already conducted a medication-related intervention on the day of the last outpatient visit.
The types of medication were subdivided into four categories: 'anticancer drugs', 'supportive care drugs', 'drugs to treat comorbidities' and 'OTC drugs [including food (supplements)]. Anticancer drugs were defined as all cytostatic, antihormonal and targeted drugs to treat malignancies, while supportive care drugs were defined as all drugs supporting the anticancer treatment (e.g. antiemetics). Drugs to treat comorbidities were defined as all agents used for noncancer disease. OTC drugs included all (herbal) drugs, food (supplements) and vitamins that were used without prescription at the time of the interview. Drugs were counted as pharmacologically active components. If one formulation contained multiple pharmacologically active ingredients, these ingredients were each counted individually in the analysis. When a drug was taken in different dosages or administration routes, it was counted as one drug.
Following the interview, the patient's medication was checked for DDIs by use of the Micromedex drug-drug interaction software program [7] . To maximize accuracy, an additional medication review was conducted by using a second drug-drug interaction software program 'www.drugs.com ' [8] .
DDIs were classified by mechanism in three major groups: pharmacokinetic DDIs, pharmacodynamic DDIs and DDIs with unknown mechanisms. Pharmacodynamic DDIs were subdivided into: (i) central nervous system (CNS) interactions, defined as combinations of drugs associated with drowsiness an increased risk of falling, (ii) QT c interactions, defined as drug combinations with potential QT c interval prolongation and/or torsades de pointes inducing properties, (iii) Gastrointestinal (GI) interactions, defined as drug combinations that may increase the risk of GI-bleeding and (iv) Other pharmacodynamic DDIs.
DDIs found in either one or both databases were counted once in the analysis. A DDI was only included in the analysis when either an 'anticancer drug' or a 'supportive care drug', as defined above, was involved. An overview of the patient's demographic characteristics, comorbidities and identified DDIs, was sent to an expert team consisting of three certified clinical pharmacologists. The expert team members first assessed the DDI lists for the need to intervene in a certain DDI based on the used medication and the individual characteristics of the patient. If the individual advices of the expert team were inconsistent, consensus had to be reached. If a DDI was identified as needing an intervention, an advice on how to manage this DDI was sent to the (hemato)oncologist in charge of the patient. In close collaboration with the expert team, the (hemato)oncologist responsible for the patient, decided whether to carry out the proposed intervention. If an intervention was carried out, the DDI was considered to be potentially clinically relevant (Figure 1 ).
statistical analysis
Descriptive statistics were used to analyze the patients' demographics, cancer type, comorbidities, number of drugs and DDI characteristics. Univariate and multivariate binary logistic regression analyses were used to identify potential determinants for DDIs leading to interventions. The dependent variable was 'the occurrence of at least one intervention per patient by the expert team' and predictor variables included age, number of drugs, number of OTC drugs, tumor type, treatment intent, type of therapy and number of comorbidities. Predictor variables with univariate P values <0.05 were stepwise included in the multivariate analysis. When the predictor variable changes the β coefficient with >10%, it was included in the multivariate model.
The primary end point in this exploratory study was the percentage of clinical intervention due to DDIs. It was estimated that DDIs would led to an intervention in 8% of all ambulatory cancer patients. With a sample size of 300 patients and an estimated intervention percentage of 8%, the 95% confidence interval for assessment of this percentage would be 5%-12%.
results

patient characteristics
A total of 368 patients were asked to participate, of which 302 patients (82%) were included in this study ( Figure 1 ). The mean age was 61 years (range 22-84 years) and half of all patients were male (Table 1 ). In total, 87% of the patients were diagnosed with a solid malignancy of which gastrointestinal, breast and genito-urinary malignancies were most frequently seen. The median number of drugs used per patient was 10 (range 1-25) and 81% of all patients used at least one OTC drug. The median number of comorbidities per patient was 1 (range 0-7) and 57% of all patients suffered from at least one comorbidity. 
drug-drug interactions
In total, 603 DDIs were identified and assessed for the need for interventions (Table 2) . Of all DDIs, 120 DDIs with a wide variety of pharmacological classes, were considered potentially clinically relevant. These 120 DDIs, present in a total of 81 patients, resulted in a clinical intervention already executed by the (hemato)oncologist in 39 patients (13%, see Figure 1 ), while an additional intervention was proposed by a clinical pharmacologist in 42 patients (14%). The (hemato)oncologist executed all interventions (100%) that were proposed by the expert team.
On the other hand, all interventions already executed by the (hemato)oncologist where retrospectively judged as potentially clinically relevant by the expert team. Coumarins, corticosteroids and NSAIDs were frequently involved in the interventions. Also OTC drugs, herbal substances and food supplements (e.g. grapefruit juice) were extensively used and frequently involved in a DDI leading to an intervention. Interestingly, none of the identified CNS interactions (n = 187) was considered to require an intervention by the expert team nor by the treating (hemato)-oncologist. In one case, a DDI (mercaptopurine and allopurinol) 
discussion
To our knowledge, this is one of the first studies that prospectively investigated the need for interventions due to DDIs in oncology. In total, 120 DDIs were considered to be potentially clinically relevant. More importantly, next to the intervention already carried out by the (hemato)oncologists themselves, this resulted in additional interventions proposed by the clinical pharmacologist in 42 patients (14%). The prevalence of DDIs is largely in accordance with similar studies [3, 4, 6] . A possible explanation for the relatively high median number of drugs used by the patients in our study might be the inclusion of herbal and other OTC drugs and the inclusion of both oral and i.v. anticancer drugs. A prospective study that looked into DDIs affecting anticancer agents concluded that the frequency of pharmacokinetic DDIs that were associated with a published clinical effect was low. However, they solely screened for pharmacokinetic DDIs and the study methods and population was highly different from the current study (e.g. different drug interaction software used, no tyrosine kinase inhibitors included and different tumor types) which may explain the relative low percentage of relevant DDIs in that study [9] . Coumarins and GI interactions (especially the combination of corticosteroids with NSAIDs), where frequently involved in an intervention, as were combinations of drugs that are known to cause QT c interval prolongation. Coumarins, which are routinely used for the treatment of thrombosis, are highly prone for DDIs with anticancer drugs. In case of a DDI between coumarins and anticancer drugs, the anticoagulant effect may be altered and a clinical intervention (by intensified monitoring of the anticoagulant effect and possible dose adjustment) is recommended. Also, NSAIDs and corticosteroids are extensively used in (hemato)oncology. When used concomitantly, gastrointestinal ulcerations or bleedings may occur and, based on patient characteristics and risk factors, an intervention (e.g. adding a proton pump inhibitor) is often required [10] . Combinations of QT c interval prolonging drugs are also frequently seen in (hemato)oncology practice. The risk of QT c interval prolongation increases by the concomitant use of more QT c interval prolonging drugs and by CYP inhibition due to another drug. Especially antiemetics (e.g. domperidone and 5HT 3 -antagonists) and certain anticancer drugs (tamoxifen, tyrosine kinase inhibitors and anthracyclines) have the capacity to prolong the QT c interval [11] . Although rare, these drug combinations can lead to QT c interval prolongation and torsades de pointes; and may therefore have severe consequences. ECG monitoring is recommended 24-48 h before, and 1 week after, the start of the concomitant use of QT c interval prolonging drugs [2] .
In accordance with previous studies, the prevalence of drug combinations, with the ability to increase the risk of falling (CNS interactions), was high in this study [3, 4] . Since co-administration of multiple central nervous depressant drugs is frequently seen and cancer patients already have an increased risk of fractures due to osteoporosis, one might expect that some of these CNS interactions were identified as potentially clinically relevant. Nevertheless, none of these CNS interactions were identified as such by the expert group. A possible explanation might be that in most cancer patients, in a certain stage of their disease, the benefits of central nervous depressant drugs, (e.g. morphine or benzodiazepines) in order to treat therapy-and disease-related side-effects, are considered to outweigh the increased risk of falling. However, withdrawal from central nervous depressant drugs may be an effective method in the prevention of falling [12] . In the future, the rational use of multiple central nervous depressant drugs in (hemato)oncology should be determined.
In order to increase accuracy, two web-based databases were used in this study to identify DDIs [7, 8] . Although Micromedex has proven to be highly accurate [13] , a more sensitive detection of QT c , GI and CNS interactions was seen when 'Drugs.com' software was used concomitantly. On the other hand, 'drugs.com' software is random in identifying other DDIs than QT c , GI and CNS interactions, which results in the detection of many irrelevant DDIs. Therefore, we recommend for future studies to use Micromedex as the basis for detecting DDIs, with additional screening for QT c , GI and CNS interactions by the 'Drugs.com' software. Even then, many clinically irrelevant DDIs will be detected, so more specific screening tools need to be developed. Clinical rules, combining DDIs with patient data (such as renal function) may be helpful [14] .
The number of comorbidities and the number of OTC drugs used concomitantly with anticancer drugs were identified as potential determinants for performing an intervention. This is consistent with other studies and not surprising since (hemato) oncologists are often not aware of the use of OTC drugs (such as complementary and alternative medicine) and that these drugs are extensively used by cancer patients and frequently involved in DDIs [4, 5, 15] . Surprisingly, the number of concomitantly used drugs was not identified as a determinant. This may be caused by the fact that the number of concomitantly used drugs and the number of comorbidities are usually highly correlated in multivariate analyses.
A strength of our study is that, for the first time, DDIs leading to an intervention by clinical pharmacologists were prospectively studied in cancer patients. Based on the actual concurrent medication used by the patient, a profound assessment was made whether to intervene or not. Also, the inclusion of OTC drugs in the analysis was important. OTC drugs are frequently used by cancer patients, are often involved in DDIs and might lead to harmful side-effects [4, 15] .
One of the limitations of this study is the lack of a control group. Due to the fact that we did not include a group in whom DDIs were identified but not reacted upon, it is not possible to assess whether or not the interventions averted any adverse drug events. More research is necessary to fully explore the effect of DDIs on adverse drug events and clinical outcome (e.g. to compare hospitalization rates). Furthermore, therapeutic drug monitoring (TDM), where blood drug concentrations and pharmacokinetic parameters are matched with pharmacodynamics (such as toxicity and clinical outcome) is a possible way to investigate the true clinical relevance of DDIs in oncology. The implementation of TDM in oncology should be further explored [5] .
Screening of DDIs by a clinical pharmacologist doubled the number of clinical interventions that were already executed by a medical oncologist. Cancer patients are often treated multidisciplinary and a sound overview of all (newly) prescribed drugs, including OTC drugs, is not always available. Subsequently, documenting all drugs, including OTC drugs in one electronic patient record and close collaboration between (hemato)oncologists and clinical pharmacologists, is necessary to facilitate a profound medication review.
In this study, the prevalence of DDIs that need intervention is high. To maximize safe and effective concomitant drug use, the Erasmus MC cancer Institute is currently implementing medication review, before and during anticancer therapy, in clinical oncology practice for all patients.
In conclusion, the present prospective study shows that, next to the intervention already carried out by the (hemato)oncologists, in 14% of patients, interventions were carried out based on recommendations of clinical pharmacologists. As the complexity of prescription process increases, more specific screening tools for the detection of DDIs are necessary, in order to increase the efficiency and cost-effectiveness of the medication The results of this study will help physicians and clinical pharmacologists to be more aware of DDIs in (hemato)oncology and should lead to a closer collaboration to identify and manage these DDIs before the start and during anticancer treatment.
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